• linkedin
  • Increase Font
  • Sharebar

    Product Preview: Agent reduces urinary oxalate excretion in stone patients

    Agent reduces urinary oxalate excretion in stone patients

    Findings from a phase IIa multicenter, open-label study demonstrated a statistically significant reduction of urinary oxalate excretion in recurrent calcium oxalate kidney stone patients with hyperoxaluria relative to baseline who were treated with ALLN-177 (p=.0084). ALLN-177 is an orally administered recombinant oxalate degrading enzyme being developed for the chronic management of hyperoxaluria and kidney stones. The agent was well tolerated and no serious adverse events were reported, according to developer Allena Pharmaceuticals, Inc.

    READ: Liquid biopsy accurately identifies high-grade prostate cancer

    AACR data: Bladder cancer test demonstrates sensitivity, specificity

    The diagnostic test PanC-Dx showed a high level of sensitivity and specificity in non-invasive detection of urothelial carcinoma, according to research presented at the American Association for Cancer Research annual meeting in Philadelphia. Another clinical trial of the test is currently enrolling patients, developer OncoCyte reported in a press release.

    Collaboration to develop prostate cancer tests announced

    CytoTest Inc., the Uniformed Services University of the Health Sciences, and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. have signed a Cooperative Research and Development Agreement (CRADA). Under the agreement, CytoTest will collaborate with the Center for Prostate Disease Research (CPDR) on the development of next-generation approaches to prostate cancer diagnosis and prognosis. As part of the initial CRADA efforts with CPDR, CytoTest will provide reagents, instrumentation, manufacturing, scale-up, biomarker screening services, and assay construction capabilities to advance the development of these markers for use in clinical diagnostic testing. The collaboration combines CPDR’s discovery and translational research abilities and unique clinical resources with CytoTest’s genomic medicine expertise and diagnostic assay development infrastructure, CytoTest said in a press release.

    NEXT: Patient enrollment complete for clinical utility study of PCa test

    Benjamin P. Saylor
    Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results